ANIXA BIOSCIENCES INC

ANIX Healthcare Biotechnology

ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.67 0.11 −3.96%
Market cap
$96.7M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
n/a
Altman Z
14.47
Beneish M
n/a
Dividend safety
n/a
Older periods Oct '25 Jan '26 Apr '26 Jul '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
7.71 11.49 9.16 7.95
Current Ratio
8.08 12.18 9.79 8.55
Net Debt/EBITDA
5.20 5.34 5.24 5.06
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.47 1.02 0.69 0.68
Capex/Depreciation
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.04) (0.08) (0.05) (0.05)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.04) (0.08) (0.05) (0.05)
Cash per Share
0.47 0.43 0.41 0.41
Shareholders Equity per Share
0.43 0.42 0.39 0.39
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.43 0.42 0.39 0.39
Free Cash Flow
(1.25) (2.61) (1.74) (1.77)
Working Capital
13.92 13.81 13.19 13.17
Net Current Asset Value
13.76 13.66 13.05 13.04
Other line items
Average Receivables
— — 0.22 —
Average Payables
0.35 0.37 0.27 0.28
Average Assets
18.84 17.07 15.92 16.36
Average Common Equity
16.42 15.28 14.07 14.31

Fold the line items

Columns are period end dates